MACK Key Statistics, Chart & Performance
The current stock price of MACK is 15.13 USD. In the past month the price increased by 2.79%. In the past year, price increased by 18.95%.
MACK Latest News, Press Relases and Analysis
MACK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About MACK
Company Profile
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2012-03-29. The firm does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The firm is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
Company Info
MERRIMACK PHARMACEUTICALS IN
One Broadway, 14th Floor
Cambridge MASSACHUSETTS 02142 US
CEO: Gary L. Crocker
Employees: 0
Phone: 16174411000
MERRIMACK PHARMACEUTICALS IN / MACK FAQ
What does MACK do?
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2012-03-29. The firm does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The firm is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.
What is the current price of MACK stock?
The current stock price of MACK is 15.13 USD.
Does MACK stock pay dividends?
MERRIMACK PHARMACEUTICALS IN (MACK) has a dividend yield of 99.8%. The yearly dividend amount is currently 0.
What is the ChartMill rating of MERRIMACK PHARMACEUTICALS IN stock?
MACK has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does MERRIMACK PHARMACEUTICALS IN belong to?
MERRIMACK PHARMACEUTICALS IN (MACK) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for MACK stock?
MERRIMACK PHARMACEUTICALS IN (MACK) currently has 0 employees.
Can you provide the upcoming earnings date for MERRIMACK PHARMACEUTICALS IN?
MERRIMACK PHARMACEUTICALS IN (MACK) will report earnings on 2024-08-01, after the market close.
MACK Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MACK. When comparing the yearly performance of all stocks, MACK turns out to be only a medium performer in the overall market: it outperformed 66.97% of all stocks.
MACK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MACK. No worries on liquidiy or solvency for MACK as it has an excellent financial health rating, but there are worries on the profitability.
MACK Financial Highlights
Over the last trailing twelve months MACK reported a non-GAAP Earnings per Share(EPS) of 13.86. The EPS increased by 10764.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 82.05% | ||
| ROE | 90.44% | ||
| Debt/Equity | 0 |